Skip to content

Microbiological Description of Sperm and Follicular Fluid Samples. Impact on IVF/ICSI Success Rates

Microbiological Description of Sperm and Follicular Fluid Samples. Impact on IVF/ICSI Success Rates (SPERMIBIOTE)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07187414
Acronym
SPERMIBIOTE
Enrollment
50
Registered
2025-09-23
Start date
2024-01-09
Completion date
2025-03-29
Last updated
2025-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

In Vitro Fertilization (IVF), Medically Assisted Procreation (MAP)

Keywords

In Vitro Fertilization (IVF), Medically Assisted Procreation (MAP), intracytoplasmic sperm injection (ICSI), microbiota

Brief summary

The goal of this observational study is to quantify and identify bacteria that may be present in semen and follicular fluid samples on the day of the IVF-ICSI attempt. The secondary objective is to : * Quantify and identify bacteria that may be present in embryo culture media on day 6. * Correlate microbiological analyses of sperm and follicular fluids with those of embryo culture media on day 6. * Evaluate their impact on fertilization and blastulation rates

Detailed description

This is a single-center observational study based on data contained in the medical records of couples treated and evaluated as part of Medically Assisted Procreation (IVF-ICSI). This study was conducted at the Parly 2 private hospital for data and sample collection, at the Parly 2 hospital microbiology laboratory, and at Life & Soft Fontenay-aux-Roses for sample analysis. Collected samples will not be stored after analysis. The objective of this study does not impose any particular constraints. The study consists of a single assessment, the data from which will be recorded on an electronic case report form (CRF).

Interventions

None listed

Sponsors

GCS Ramsay Santé pour l'Enseignement et la Recherche
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 59 Years
Healthy volunteers
No

Inclusion criteria

* Man aged 18 to 59 who have provided a sperm sample after an abstinence period of between 2 and 7 days. Sperm prepared by density gradient on day 0. Negative sperm culture (\<6 months). No specific urogenital history (varicocele, cryptorchidism, testicular ectopia, etc.). * Women aged 18 to 43 undergoing oocyte puncture with collection of follicular fluid on day 0. No endometriosis or hydrosalpinx. Negative vaginal sample (\< 6 months). * Negative HIV, HBV, and HCV serology tests within the last year. * Absence of urinary tract infections in men and sexually transmitted infections (HPV, HSV, HIV-1/2, C. trachomatis, Gonorrhea, Syphilis, etc.) (\<6 months). * Absence of recent antibiotic or antifungal treatment (end of treatment \< 3 months) Absence of probiotic intake (\< 3 months). * No history of chemotherapy or radiation therapy. * Embryonic culture performed up to day 6 for all zygotes.

Exclusion criteria

* Homosexual patient couples or transsexual couples * Patients treated for medically assisted procreation with a third-party donor * Frozen sperm pellets (ejaculate or surgical) * Donor sperm * Sperm prepared by washing * Abstinence period \<2 or \>7 days * Fever \<3 months * History of chemotherapy or radiotherapy. * History of urinary tract infections in man (\< 6 months) * History of sexually transmitted infections (HPV, HSV, HIV-1/2, C. trachomatis, gonorrhea, syphilis, etc.) (\<6 months) * Specific urogenital history (varicocele, cryptorchidism, testicular ectopia, etc.) * Recent antibiotic therapy or antifungal treatment (end of treatment \< 3 months) * Taking probiotics (end of treatment \< 3 months) * Positive sperm culture \< 6 months. * Positive vaginal sample \< 6 months. White puncture. * Collection failure. * Fertilization failure

Design outcomes

Primary

MeasureTime frameDescription
Quantification and identification of bacteria present in semen and follicular fluid samples on the day of the IVF-ICSI attempt.Day 0Analysis of sequences of bacteria identified by amplification and sequencing of the gene encoding 16S rRNA in aliquots taken on day 0.

Secondary

MeasureTime frameDescription
Quantification and identification of bacteria present in semen and follicular fluid samples on the day 6 after of the IVF-ICSI attempt.Day 6Description: Analysis of sequences of bacteria identified by amplification and sequencing of the gene encoding 16S rRNA in aliquots taken on day 6.
IVF/ICSI success rateDay 6presence of a morula on day 6

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026